|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-3.23/-2.54
|
企業價值
7.34B
|
資產負債 |
每股賬面淨值
-5.61
|
現金流量 |
現金流量率
--
|
損益表 |
收益
9.30M
|
每股收益
0.05
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 01:12 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Itsproduct pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. |